Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis
- PMID: 27060790
- PMCID: PMC4826453
- DOI: 10.1093/cid/ciw066
Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis
Erratum in
-
Hammarlund E et al (Clin Infect Dis 2016; 62:1111-8).Clin Infect Dis. 2016 Jul 1;63(1):150. doi: 10.1093/cid/ciw269. Epub 2016 May 8. Clin Infect Dis. 2016. PMID: 27161783 Free PMC article. No abstract available.
Abstract
Background: Many adult immunization schedules recommend that tetanus and diphtheria vaccination be performed every 10 years. In light of current epidemiological trends of disease incidence and rates of vaccine-associated adverse events, the 10-year revaccination schedule has come into question.
Methods: We performed cross-sectional analysis of serum antibody titers in 546 adult subjects stratified by age or sex. All serological results were converted to international units after calibration with international serum standards.
Results: Approximately 97% of the population was seropositive to tetanus and diphtheria as defined by a protective serum antibody titer of ≥0.01 IU/mL. Mean antibody titers were 3.6 and 0.35 IU/mL against tetanus and diphtheria, respectively. Antibody responses to tetanus declined with an estimated half-life of 14 years (95% confidence interval, 11-17 years), whereas antibody responses to diphtheria were more long-lived and declined with an estimated half-life of 27 years (18-51 years). Mathematical models combining antibody magnitude and duration predict that 95% of the population will remain protected against tetanus and diphtheria for ≥30 years without requiring further booster vaccination.
Conclusions: These studies demonstrate that durable levels of protective antitoxin immunity exist in the majority of vaccinated individuals. Together, this suggests that it may no longer be necessary to administer booster vaccinations every 10 years and that the current adult vaccination schedule for tetanus and diphtheria should be revisited.
Keywords: cross-sectional analysis; diphtheria; immunological memory; tetanus.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
Figures
Similar articles
-
Fifth vaccination with dipthteria, tetanus and acellular pertussis is beneficial in four- to six-year-olds.Pediatr Infect Dis J. 2001 Apr;20(4):427-33. doi: 10.1097/00006454-200104000-00011. Pediatr Infect Dis J. 2001. PMID: 11332669
-
Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.Pediatr Infect Dis J. 1998 Apr;17(4):294-304. doi: 10.1097/00006454-199804000-00006. Pediatr Infect Dis J. 1998. PMID: 9576383 Clinical Trial.
-
Low seroprevalence of diphtheria, tetanus and pertussis in ambulatory adult patients: the need for lifelong vaccination.Eur J Intern Med. 2014 Jul;25(6):528-32. doi: 10.1016/j.ejim.2014.04.010. Epub 2014 May 9. Eur J Intern Med. 2014. PMID: 24814432
-
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000. Drugs. 2012. PMID: 22931522 Review.
-
High tetanus and diphtheria antitoxin concentrations in Finnish adults--time for new booster recommendations?Vaccine. 2009 Aug 27;27(39):5295-8. doi: 10.1016/j.vaccine.2009.06.080. Epub 2009 Jul 9. Vaccine. 2009. PMID: 19596410 Review.
Cited by
-
A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.Vaccine X. 2024 Sep 26;20:100556. doi: 10.1016/j.jvacx.2024.100556. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39444596 Free PMC article. Review.
-
Overuse of tetanus toxoid vaccine: a common but under-addressed issue in Nepal.Ann Med Surg (Lond). 2024 Sep 4;86(10):6276-6279. doi: 10.1097/MS9.0000000000002525. eCollection 2024 Oct. Ann Med Surg (Lond). 2024. PMID: 39359813 Free PMC article.
-
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study.Vaccines (Basel). 2024 Sep 19;12(9):1070. doi: 10.3390/vaccines12091070. Vaccines (Basel). 2024. PMID: 39340100 Free PMC article.
-
Tetanus-diphtheria vaccine can prime SARS-CoV-2 cross-reactive T cells.Front Immunol. 2024 Jul 18;15:1425374. doi: 10.3389/fimmu.2024.1425374. eCollection 2024. Front Immunol. 2024. PMID: 39091504 Free PMC article.
-
A genetically engineered neuronal membrane-based nanotoxoid elicits protective immunity against neurotoxins.Bioact Mater. 2024 May 9;38:321-330. doi: 10.1016/j.bioactmat.2024.05.006. eCollection 2024 Aug. Bioact Mater. 2024. PMID: 38764446 Free PMC article.
References
-
- Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298:2155–63. - PubMed
-
- Wassilak SG, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008.
-
- Vaccine Safety Committee. Diphtheria and tetanus toxoids. Adverse events associated with childhood vaccines: evidence bearing on causality. In: Stratton KR, Howe CJ, Johnston RB, eds. Research strategies for assessing adverse effects associated with vaccines. Washington, DC: National Academy Press, 1994:67–117.
-
- National Communicable Disease Center. Recommendation of Public Health Service Advisory Committee on Immunization Practices: diphtheria, tetanus, and pertussis vaccines: tetanus prophylaxis in wound management. MMWR Morb Mortal Wkly Rep 1966; 15:416–8.
-
- Peebles TC, Levine L, Eldred MC, Edsall G. Tetanus-toxoid emergency boosters: a reappraisal. N Engl J Med 1969; 280:575–81. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
